论文部分内容阅读
目的探讨血清肿瘤标志物在肺癌诊断中的临床价值。方法收集40例健康人、45例肺部良性疾病患者和90例肺癌患者,采用电化学发光分析检测患者血清中肿瘤标志物细胞角蛋白19(CYFRA21-1)、鳞状细胞癌相关抗原(SCC)和癌胚抗原(CEA),以及胃泌素释放肽前体(pro-GRP)和神经元特异性烯醇化酶(NSE)的含量。结果健康人组和肺部良性疾病患者组血清NSE、pro-GRP、CYFRA21-1、SCC和CEA水平较肺癌患者组水平低,差异有统计学意义(P<0.01)。NSE和pro-GRP在小细胞肺癌患者中的水平均明显高于其他类型的肺癌患者(P<0.01),CYFRA21-1和SCC在鳞癌患者中的含量比其他类型肺癌患者高(P<0.01)。联合检测此5种血清肿瘤标志物敏感性高于单独的肿瘤标志物(P<0.01)。结论联合检测NSE、pro-GRP、CYFRA21-1、SCC和CEA可以提高肺癌诊断的灵敏度。
Objective To investigate the clinical value of serum tumor markers in the diagnosis of lung cancer. Methods Forty healthy people, 45 benign pulmonary disease patients and 90 lung cancer patients were collected. The serum levels of cytokeratin 19 (CYFRA21-1), squamous cell carcinoma associated antigen (SCC) ) And carcinoembryonic antigen (CEA), as well as the levels of pro-GRP and NSE. Results The levels of serum NSE, pro-GRP, CYFRA21-1, SCC and CEA in healthy group and patients with benign lung disease were significantly lower than those in patients with lung cancer (P <0.01). The levels of NSE and pro-GRP in patients with SCLC were significantly higher than those in other types of patients with lung cancer (P <0.01). The levels of CYFRA21-1 and SCC in patients with SCC were higher than those in other types of patients with lung cancer (P <0.01) ). The joint detection of these 5 serum tumor markers was more sensitive than the single tumor markers (P <0.01). Conclusion The combined detection of NSE, pro-GRP, CYFRA21-1, SCC and CEA can improve the sensitivity of lung cancer diagnosis.